Vivek Subbiah: Think Tank on Advancing precision medicine in Rare cancers spearheaded by the amazing Jim Palma and Razelle Kurzrock

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post by Jim Palma on LinkedIn:

“So honored to deliver the Scientific Keynote.
“Future-Proofing Healthcare: A Vision of Patient-Centric Tissue-Agnostic Precision Medicine” At the Target Cancer Foundation Think Tank on Advancing hashtag precision medicine in Rare cancers spearheaded by the amazing Jim Palma and Razelle Kurzrock.

• The Think Tank on Advancing Precision Medicine in Rare Cancers is a highly interactive, one-day meeting uniting clinicians, researchers, industry, patient advocates and patients in a unique format to promote collaboration, information sharing, and idea generation.
• The diverse perspectives of speakers and attendees allows for a comprehensive discussion of challenges, goals, opportunities and best practices in addressing the needs of patients facing rare cancers.
• The Think Tank on Advancing Precision Medicine in Rare Cancers leverages the successful “think tank” model that Target Cancer Foundation has established through over a decade of meetings on other topics, such as gastroesophageal cancers.
• This meeting also builds on the progress being made through Target Cancer Foundation’s TCF-001 TRACK study, a nationwide, decentralized, patient-driven clinical trial studying precision medicine in rare cancers.”

Quoting Jim Palma’s post:

“I’ve been incredibly fortunate over the past several years to have the opportunity to work closely with Vivek Subbiah through his role as Co-PI and Molecular Tumor Board member on our TCF-001 TRACK clinical trial. I’m especially excited and grateful that he will be providing the Scientific Keynote at our upcoming Think Tank on Advancing Precision Medicine in Rare Cancers, happening in Boston on November 15!

Registration is open for this unique, interactive meeting- learn more and register here.”

Source: Vivek Subbiah/LinkedIn and Jim Palma/LinkedIn.